ESR1 and breast carcinoma: First, we showed that CB-839 treatment has a differential effect on the growth of two patient-derived xenograft (PDX) models of breast cancer representing luminal-like, ER+ (MAS98.06) and basal-like, triple-negative (MAS98.12) breast cancer.